8-K: Zynex SEC Investigation Concludes Amid Bankruptcy

Zynex, Inc. announced the conclusion of an SEC investigation with no enforcement action intended, amidst ongoing Chapter 11 bankruptcy proceedings and delisting from Nasdaq.

Summary

• The U.S. Securities and Exchange Commission (SEC) concluded its investigation into Zynex, Inc. on February 18, 2026, and does not intend to recommend an enforcement action against the company.
• Zynex's common stock was delisted from The Nasdaq Stock Market LLC on December 17, 2025, as a result of the company and certain subsidiaries commencing voluntary Chapter 11 bankruptcy cases on December 15, 2025.
• Following delisting, the company's common stock was suspended from trading on Nasdaq and began trading on the Pink Limited Market, operated by OTC Markets Group, under the symbol ZYXIQ on December 24, 2025.
• Nasdaq filed a Form 25 with the SEC on January 23, 2026, which became effective on February 2, 2026, initiating the deregistration of the common stock under Section 12(b) of the Securities Exchange Act of 1934.
• The company cautions that trading in its securities during the Chapter 11 cases is highly speculative and poses substantial risks, with equity holders expected to experience a significant loss on their investment if restructuring transactions are implemented.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as overwhelmingly negative due to the ongoing Chapter 11 bankruptcy, delisting, and explicit warning of significant loss for equity holders, despite the positive news of the SEC investigation concluding without enforcement action.

Positives

• The U.S. Securities and Exchange Commission has concluded its investigation into Zynex, Inc. and does not intend to recommend an enforcement action against the company.

Negatives

• Zynex's common stock was delisted from The Nasdaq Stock Market LLC on December 17, 2025, due to the company's Chapter 11 bankruptcy filing.
• The common stock was suspended from trading on Nasdaq and began trading on the Pink Limited Market under the symbol ZYXIQ on December 24, 2025.
• Deregistration of the common stock under Section 12(b) of the Securities Exchange Act of 1934 is underway, effective 90 days (or shorter) after February 2, 2026.
• The company cautions that trading in its securities during Chapter 11 is highly speculative and poses substantial risks.
• Equity holders are expected to experience a significant loss on their investment if the restructuring transactions are implemented.

Risks

• Trading in the company's securities during the Chapter 11 cases is highly speculative and poses substantial risks.
• Trading prices for the company's securities may bear little or no relationship to the actual recovery, if any, by holders of the company's securities in the Chapter 11 Cases.
• Equity holders are expected to experience a significant loss on their investment if the restructuring transactions are implemented.
• Risks and uncertainties relating to the Chapter 11 Cases, including the company's ability to obtain bankruptcy court approval for motions and confirmation of the plan of reorganization.
• Uncertainty regarding the effects of the Chapter 11 Cases on the company and its various constituents.
• Impact of bankruptcy court rulings in the Chapter 11 Cases.
• The ultimate outcome of the Chapter 11 Cases in general.
• The length of time the company will operate under the Chapter 11 Cases.
• Attendant risks associated with restrictions on the company's ability to pursue its business strategies while the Chapter 11 Cases are pending.
• Risks associated with third-party motions in the Chapter 11 Cases.
• The potential adverse effects of the Chapter 11 Cases on the company's liquidity.
• The likelihood of the cancellation of the company's common stock in the Chapter 11 Cases.
• Uncertainty regarding the company's ability to retain key personnel and management.
• Uncertainty and continuing risks associated with the company's ability to achieve its goals and continue as a going concern.

Future Outlook

The company expects its equity holders to experience a significant loss on their investment if the restructuring transactions contemplated by the Chapter 11 Cases are implemented. The ability to complete restructuring, obtain court and stakeholder approval, and confirm the plan of reorganization are uncertain. The company faces risks related to its liquidity, ability to retain key personnel, and its capacity to continue as a going concern during and after the Chapter 11 proceedings.

Management Comments

• "Trading in the Company's securities during the pendency of the previously disclosed Chapter 11 cases... is highly speculative and poses substantial risks."
• "Trading prices for the Company's securities may bear little or no relationship to the actual recovery, if any, by the holders of the Company's securities in the Chapter 11 Cases."
• "The Company expects that its equity holders will experience a significant loss on their investment if the restructuring transactions contemplated by the Chapter 11 Cases... are implemented."

Industry Context

StockSavvy.ai notes that the conclusion of an SEC investigation without enforcement action is a positive development for any company, especially one undergoing Chapter 11 bankruptcy. However, this positive is heavily overshadowed by the severe financial distress indicated by the delisting and bankruptcy filing, which typically signals a complete loss for equity holders in the medical device or healthcare sector.

Comparison to Industry Standards

• The delisting from Nasdaq and subsequent trading on the Pink Limited Market is a severe downgrade, typically seen in companies facing significant financial distress or regulatory non-compliance, unlike established peers in the medical device industry such as Medtronic or Johnson & Johnson, which maintain strong exchange listings.
• The expectation of significant loss for equity holders in Chapter 11 is a common outcome in corporate bankruptcies across industries, aligning with the typical hierarchy of claims where secured creditors and bondholders are prioritized over common shareholders.
• The conclusion of an SEC investigation without enforcement action, while positive, does not mitigate the fundamental financial challenges, unlike companies that successfully navigate regulatory scrutiny while maintaining operational and financial stability.

Legal Proceedings

• The company is undergoing voluntary Chapter 11 bankruptcy cases.
• The SEC has concluded its investigation into the company and does not intend to recommend an enforcement action.

Stakeholder Impact

• Shareholders: Expected to experience a significant loss on their investment, with the likelihood of common stock cancellation in the Chapter 11 Cases. Trading is highly speculative.
• Management/Key Personnel: Uncertainty regarding the company's ability to retain key personnel and management during Chapter 11.
• Creditors: The restructuring transactions will determine the recovery for various classes of creditors, with equity holders being subordinate.

Next Steps

• Completion of restructuring transactions contemplated by the Chapter 11 Cases.
• Obtaining bankruptcy court approval for motions and confirmation of the plan of reorganization.
• Deregistration of common stock under Section 12(b) of the Securities Exchange Act of 1934, effective 90 days (or shorter) after February 2, 2026.

Key Dates

Recommendation

The company is in Chapter 11 bankruptcy, has been delisted from Nasdaq, and explicitly warns that equity holders are expected to experience a significant loss, with the likelihood of common stock cancellation. While the SEC investigation conclusion is a minor positive, it does not outweigh the fundamental financial distress and near-certain loss for current shareholders.

Keywords

Zynex, ZYXIQ, SEC investigation, Chapter 11, bankruptcy, delisting, OTC Markets, restructuring, equity loss, financial risk